Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

Also called NCT02586233

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 106 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02586233
  • EudraCT 2015-001824-43
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Czechia, France, Germany, Italy, Slovakia, South Korea, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02586233. Randomized; double masking; primary purpose treatment. Start 2015-09 (actual); primary completion 2019-08-13 (actual). Results posted on 2020-09-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
Acronym
ASSENT
Condition
Acute Ischemic Stroke
Condition
Thrombotic Disease
Intervention (Drug)
DS-1040b
Intervention (Drug)
Placebo
Lead sponsor
Daiichi Sankyo (class: industry)

Record details

Record id
cardio:ct-nct02586233
Content hash
4d6d5f65d342645ab2f288418ce2a7759e2d50f25ec6ebb21d0b620502014218